Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.
Bipolar Disorder
/ drug therapy
Cognition Disorders
/ physiopathology
Depressive Disorder, Major
/ physiopathology
Humans
Hypothyroidism
/ complications
Mood Disorders
/ physiopathology
Prolactin
/ blood
Psychotic Disorders
/ drug therapy
Schizophrenia
/ drug therapy
Thyroid Hormones
/ blood
Triiodothyronine
/ blood
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
pubmed:
16
10
2019
medline:
3
6
2020
entrez:
16
10
2019
Statut:
ppublish
Résumé
Cognitive deficits are a core feature of serious mental illnesses such as major depression, bipolar disorder and schizophrenia and are a common cause of functional disability. However, the efficacy of pharmacological interventions for improving the cognitive deficits in these disorders is limited. As pro-cognitive pharmacological treatments are lacking, we aimed to review whether thyroid hormones or drugs that target prolactin may become potential candidates for 'repurposing' trials aiming to improve cognition. We conducted a narrative review focused on thyroid hormones and prolactin as potential targets for improving cognition in major mood disorders or schizophrenia. The role of thyroid hormones and prolactin on cognitive processes in non-psychiatric populations was also reviewed. Although clinical trials regarding these hormones are lacking, particularly in patients with schizophrenia, bipolar disorder or major depression, there is evidence from observational studies for the contribution of these hormones to cognitive processes. Patients with bipolar disorder and subclinical hypothyroidism show poorer cognitive function than euthyroid patients. In patients with early psychosis, lower free thyroxine concentrations have been associated with poorer attention whereas increased prolactin levels have been associated with poorer speed of processing. Only two small clinical trials tested the potential pro-cognitive effects of thyroid hormones, with positive findings for triiodothyronine (T3) treatment in patients receiving lithium or electroconvulsive therapy. In sum, thyroid hormones and prolactin might contribute to the cognitive performance of patients with major mood disorders and psychotic disorders. Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia.
Identifiants
pubmed: 31612424
doi: 10.1007/s40261-019-00854-w
pii: 10.1007/s40261-019-00854-w
doi:
Substances chimiques
Thyroid Hormones
0
Triiodothyronine
06LU7C9H1V
Prolactin
9002-62-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-14Subventions
Organisme : Instituto de Salud Carlos III
ID : PI15/01386
Organisme : Departament de Salut, Generalitat de Catalunya
ID : SLT006/17/00012
Investigateurs
Pilar Álvarez
(P)
Juan David Barbero
(JD)
Miquel Bioque
(M)
Jesús Cobo
(J)
Núria Del Cacho
(N)
Clemente García-Rizo
(C)
Javier Labad
(J)
Ana Martín-Blanco
(A)
José Antonio Monreal
(JA)
Itziar Montalvo
(I)
Maria Portella
(M)
Eva Real
(E)
Elena Rubio
(E)
Virginia Soria
(V)
Judith Usall
(J)
Références
Biol Psychol. 2014 Dec;103:158-66
pubmed: 25196100
BMC Psychiatry. 2004 Aug 18;4:25
pubmed: 15317653
Front Endocrinol (Lausanne). 2016 Mar 30;7:25
pubmed: 27065946
Schizophr Res. 2010 May;118(1-3):189-200
pubmed: 20189356
J Thyroid Res. 2011;2011:306367
pubmed: 21808723
Clin Psychopharmacol Neurosci. 2013 Aug;11(2):60-6
pubmed: 24023549
PLoS One. 2014 Feb 24;9(2):e89428
pubmed: 24586772
Front Neurol. 2018 Jan 29;8:742
pubmed: 29434564
Neurochem Res. 2014 Jul;39(7):1245-53
pubmed: 24723220
J Clin Invest. 2019 Jan 2;129(1):230-245
pubmed: 30352046
BMC Psychiatry. 2004 Mar 15;4:6
pubmed: 15113438
Eur J Endocrinol. 2009 Dec;161(6):917-21
pubmed: 19755406
Clin Endocrinol (Oxf). 2004 Jun;60(6):750-7
pubmed: 15163340
Eur J Pharmacol. 1988 Apr 27;149(1-2):1-8
pubmed: 2456219
Mol Psychiatry. 2005 May;10(5):456-69
pubmed: 15724143
Psychoneuroendocrinology. 2019 Apr;102:24-36
pubmed: 30503781
Biol Psychiatry. 1988 Aug;24(4):415-22
pubmed: 2900656
Exp Clin Psychopharmacol. 2013 Aug;21(4):332-41
pubmed: 23834553
Clin Drug Investig. 2017 Aug;37(8):713-727
pubmed: 28477315
Psychoneuroendocrinology. 2018 Jul;93:8-19
pubmed: 29680774
Psychoneuroendocrinology. 2015 Aug;58:130-40
pubmed: 25981348
Eur Neuropsychopharmacol. 2012;22 Suppl 3:S499-504
pubmed: 22959115
Thyroid. 2013 May;23(5):562-5
pubmed: 23627903
Aust N Z J Psychiatry. 1994 Dec;28(4):620-4
pubmed: 7794205
J Clin Endocrinol Metab. 2015 Nov;100(11):4240-8
pubmed: 26305618
J Clin Endocrinol Metab. 2009 May;94(5):1623-9
pubmed: 19190113
Transl Psychiatry. 2015 Apr 28;5:e555
pubmed: 25918992
Endocrinol Metab Clin North Am. 2014 Jun;43(2):529-43
pubmed: 24891176
Schizophr Res Cogn. 2015 Dec 17;2(4):172-178
pubmed: 29114461
Psychoneuroendocrinology. 2015 Sep;59:71-80
pubmed: 26036452
Behav Brain Res. 2013 Sep 1;252:32-9
pubmed: 23711928
Int Clin Psychopharmacol. 2018 Mar;33(2):98-102
pubmed: 29035904
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7250-4
pubmed: 2780568
Psychoneuroendocrinology. 2015 Jan;51:351-64
pubmed: 25462907
Thyroid. 2014 Dec;24(12):1670-751
pubmed: 25266247
Prog Neurobiol. 2016 Sep;144:48-67
pubmed: 26969413
Aust N Z J Psychiatry. 2018 Jun;52(6):585-595
pubmed: 29232966
Mol Psychiatry. 2016 Feb;21(2):229-36
pubmed: 25600111
Neurology. 2016 Feb 23;86(8):731-4
pubmed: 26701376
Horm Behav. 2013 Nov;64(5):781-9
pubmed: 24144492
Neuropsychopharmacology. 1998 Jun;18(6):444-55
pubmed: 9571653
J Neuroendocrinol. 2015 Jun;27(6):435-45
pubmed: 25855519
Dialogues Clin Neurosci. 2017 Mar;19(1):55-63
pubmed: 28566947
Brain Cogn. 2014 Feb;84(1):76-84
pubmed: 24321198
Psychiatry Res. 1990 Jun;32(3):241-51
pubmed: 2201988
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):170-4
pubmed: 22750309
Transl Psychiatry. 2017 Jan 24;7(1):e1011
pubmed: 28117843
Schizophr Res. 2015 Aug;166(1-3):37-42
pubmed: 25982813
BJPsych Open. 2016 Mar 9;2(2):139-146
pubmed: 27703766
J Clin Endocrinol Metab. 2009 Oct;94(10):3789-97
pubmed: 19584178
Psychoneuroendocrinology. 2003 Jan;28 Suppl 1:53-67
pubmed: 12504072
J Psychiatr Pract. 2005 Jul;11(4):241-7
pubmed: 16041234
Endocr Pract. 2012 Nov-Dec;18(6):988-1028
pubmed: 23246686
Neuropsychopharmacology. 2002 Oct;27(4):620-8
pubmed: 12377398
Clin Chim Acta. 2015 Apr 15;444:78-80
pubmed: 25677864
Neurosci Biobehav Rev. 2014 Mar;40:62-79
pubmed: 24480318
Schizophr Res. 2016 Mar;171(1-3):182-6
pubmed: 26805411
Int J Neuropsychopharmacol. 2000 Jun;3(2):175-186
pubmed: 11343594
Eur J Pharmacol. 1990 Oct 23;187(3):399-408
pubmed: 1981553
Arch Gen Psychiatry. 1990 May;47(5):435-40
pubmed: 2184796
J Neurosci. 2009 Feb 11;29(6):1826-33
pubmed: 19211889
Vitam Horm. 2018;106:313-331
pubmed: 29407440
Arch Med Sci. 2012 Dec 20;8(6):1096-101
pubmed: 23319987
FASEB J. 2016 Feb;30(2):1002-10
pubmed: 26567005
Eur J Endocrinol. 2005 Dec;153(6):747-53
pubmed: 16322379
Schizophr Res. 2017 Nov;189:117-125
pubmed: 28755878
Behav Neurosci. 2012 Feb;126(1):73-85
pubmed: 21928875
J Gerontol A Biol Sci Med Sci. 2005 Mar;60(3):385-90
pubmed: 15860479
Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):378-80
pubmed: 18585544
Eur Cytokine Netw. 2004 Apr-Jun;15(2):99-104
pubmed: 15319167
Psychiatry Res. 2014 Sep 30;219(1):109-13
pubmed: 24913831
Schizophr Res. 2016 Jul;174(1-3):156-160
pubmed: 27068570
Psychoneuroendocrinology. 2011 Nov;36(10):1530-9
pubmed: 21621331
J Psychiatr Res. 2015 Feb;61:166-7
pubmed: 25563517
Eur Thyroid J. 2013 Dec;2(4):215-28
pubmed: 24783053
Psychiatr Danub. 2015 Sep;27 Suppl 1:S261-5
pubmed: 26417776
Drugs. 1998;55 Suppl 1:10-6
pubmed: 9483165
Brain. 2006 Nov;129(Pt 11):2923-30
pubmed: 16921178
Br J Psychiatry. 2009 Dec;195(6):475-82
pubmed: 19949193
Schizophr Res. 2012 Jan;134(1):16-9
pubmed: 21831600
Front Endocrinol (Lausanne). 2014 Mar 31;5:40
pubmed: 24744751
Endocrine. 2017 Aug;57(2):199-213
pubmed: 28634745
Curr Drug Saf. 2012 Apr;7(2):92-8
pubmed: 22873493
Bipolar Disord. 2016 Jun;18(4):352-62
pubmed: 27237705
Schizophr Res. 2017 Nov;189:111-116
pubmed: 28214176
Dialogues Clin Neurosci. 2015 Jun;17(2):111-26
pubmed: 26246787
Lancet Psychiatry. 2016 Feb;3(2):171-8
pubmed: 26851330
Biol Psychiatry. 1991 Sep 15;30(6):623-7
pubmed: 1932410
J Clin Endocrinol Metab. 2012 Jul;97(7):2256-71
pubmed: 22593590
Eur J Endocrinol. 2011 Jun;164(6):951-9
pubmed: 21474509
Psychoneuroendocrinology. 2013 Sep;38(9):1717-28
pubmed: 23490072
Psychopharmacology (Berl). 2011 Dec;218(3):567-78
pubmed: 21611724
Thyroid. 1998 Oct;8(10):909-13
pubmed: 9827658
Aust N Z J Psychiatry. 1996 Apr;30(2):246-52
pubmed: 8811268
Biol Psychiatry. 2003 May 15;53(10):899-905
pubmed: 12742677
Schizophr Bull. 2010 Jan;36(1):112-25
pubmed: 19767349
Psychol Med. 2013 Dec;43(12):2571-82
pubmed: 23590895
PLoS One. 2012;7(9):e44371
pubmed: 22973440
Neuroimmunomodulation. 2008;15(2):131-9
pubmed: 18679052